Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Changes in Beneficial Ownership · 4

Apollomics Inc.

APLMNASDAQEQUITYCurrent

Changes in Beneficial Ownership

Filed Jun 16, 2026Accepted Jun 16, 2026, 5:01 PM EDTFiling CIK 1944885Accession 0001193125-26-272821
Share

Structured filing — 4

ownership.xml

Open full document ↗

Filing details

Report period
2026-06-15
Issuer
Apollomics Inc.
Issuer CIK
0001944885
Trading symbol
APLM

Reporting owner 1

Name
Jan Chen-Huan
Reporting owner CIK
0002115367
Relationship
Director
Address
989 E HILLSDALE BLVD, SUITE 220, FOSTER CITY, CA, 94404

Non-derivative transactions

Non-derivative transactions · 1 reported row
SecurityTransaction dateCodeAmountA / DPrice (USD)Owned afterOwnership
CLASS A ORDINARY SHARES2026-06-15M · Form 4500A01,500D
Table key
M · Form 4
Exempt derivative exercise or conversion under Rule 16b-3
A
Acquired
D
Direct

Derivative transactions

Derivative transactions · 1 reported row
SecurityConversion / exercise price (USD)Transaction dateCodeAmountA / DPrice (USD)ExercisableExpiresUnderlying securityUnderlying sharesOwned afterOwnership
Restricted Stock Units[F1]2026-06-15M · Form 4500D0[F2][F2]CLASS A ORDINARY SHARES500500D
Table key
M · Form 4
Exempt derivative exercise or conversion under Rule 16b-3
D
Direct

Footnotes

F1
Each restricted stock unit represents a contingent right to receive one Class A Ordinary Share↩ 1
F2
RSUs were granted and previously reported on a Form 3 filed March 18, 2026 and a Form 3/A filed April 14, 2026. Of the initial RSU grant, 500 shares vested on each of February 9, 2026, March 15, 2026 and June 15, 2026 and an additional 500 shares will vest on September 15, 2026. This transaction represents the vesting of 500 RSUs on June 15, 2026.↩ 1↩ 2

Signature 1

Signed
/s/ Alison M. Pear, Attorney-In-Fact
Date
2026-06-16

Company context

Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics’ lead program is vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, which is currently in a Phase 2 multicohort clinical trial in the United States and other countries.

Current securities

Recent company filings

  1. 6-K filingNov 6, 2026
  2. 424B3 filingSep 8, 2026
  3. D filingAug 19, 2026
  4. SCHEDULE 13D/A - filed by Chen Yi-Kuei regarding Apollomics Inc.Aug 14, 2026
  5. 6-K filingAug 12, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.